UNIVERSITE SCIENCES TECHNOLOGIES LILLE;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -;INSTITUT GUSTAVE ROUSSY;CELLVAX;UNIVERSITE DU DROIT ET DE LA SANTE LILLE 2;UNIVERSITE PARIS-SUD
The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.